Hypothesis-Generating Brief: Cardiovascular Subgroups

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile directional coding for Zheng 2025: the bundle reports adverse detraining effects on SBP, DBP, lipids, and body fat, so the 'null on detraining-neutral contrasts' framing must be corrected to 'adverse on detraining,' and the conflict map involving Zheng 2025 vs. Wolfe 2025 should be re-stated.
2. Disambiguate the two Chen 2026 bundle entries by giving them distinct cited_as labels (e.g., Chen 2026a for sarcopenia-CKM and Chen 2026b for resting heart rate) and reconcile any in-text claims that depend on one vs. the other.
3. Re-verify the directional coding for Young 2026: the OLIVAUS DII secondary analysis bundle does not support a 'negative anthropometric-CVD' claim direction, and the severity-5 conflict with Delaney 2025 should be re-examined or the source removed from that conflict pair.
4. Reconcile the directness counts in the Findings Map with the abstract's '58/64 indirect' headline by producing a single, consistent accounting of direct/indirect/review/protocol/mechanistic sources across all slices.
5. Fix the admissions-funnel presentation: either provide a true PRISMA-style exclusion cascade with mutually exclusive and additive rows, or remove the table and replace with a textual description that does not invite arithmetic scrutiny.
6. Resolve the within-class directional conflict between Tuesta-Nole 2026 (null) and Holley 2026 (positive for CV events on levothyroxine) explicitly in the Longevity subsection rather than letting the two coexist without comparison.
7. Tighten source attribution: every source listed in the Findings Map rows should have at least one in-text sentence with a specific finding attributed to it; remove or relocate sources that contribute no mapped finding.
8. Verify or remove the '376 claim-level cross-study disagreements' figure, or replace it with the count of actually surfaced named tensions so the Gaps section does not overstate its quantitative content.
9. Clarify the apparent Ward 2026 / Filev 2026 duplication and ensure each cited_as label maps to exactly one bundle entry.

Major issues

• Citation inconsistency: 'Young 2026' is cited as a negative anthropometric-CVD source and as disagreeing with Delaney 2025, but the bundle entry (Holley 2026 is also mislabeled; the OLIVAUS olive oil trial) actually corresponds to the Young 2026 cited_as entry, which is about DII and blood pressure in Australian adults — the 'negative anthropometric-CVD' claim is not supported by the bundle excerpt, suggesting author-year sloppiness or fabricated direction tags.
• Two distinct Chen 2026 entries appear in the bundle (NHANES/CHARLS sarcopenia-CKM paper and a Resting Heart Rate NHANES paper), both cited_as 'Chen 2026', creating citation ambiguity that undermines the per-source audit trail the manuscript claims.
• The Cardiometabolic section claims 'You 2026 (negative), Liu 2026b (negative), and Young 2026 (negative) directly disagree with Wolfe 2025 (null) and Zheng 2025 (null) — partial conflicts carried in the cross-study disagreement map at severity 4' and also 'disagree with Delaney 2025 (positive) ... a direct conflict at severity 5.' Wolfe 2025 bundle entry describes ASPREE extended follow-up, which does report a null in-trial MACE effect; Zheng 2025 detraining bundle reports adverse SBP/DBP increases — Zheng 2025 is not null and is in fact adverse, so the directional coding 'null on detraining-neutral contrasts' misrepresents the source.
• The abstract and scope state '58/64 retained sources are indirect, review-level, adjacent, or mechanistic' but the Findings Map reports only 6 direct human evidence sources, while the rows show a mix of 3 direct, 4 indirect, 10 review for cardiometabolic — these counts do not reconcile cleanly with the headline 58/64 figure.
• Admissions funnel arithmetic: 67 classified candidates cannot yield 64 admitted sources after only 10 no-extractable, 3 none-only, 70 mixed-partial, 7 partial-only exclusions — the funnel table is internally inconsistent and the manuscript acknowledges the rows 'are not an additive conservation table,' which is a methodological transparency flag rather than a clean PRISMA-ScR report.

Minor issues

• Several sources cited in the Findings Map (Salerno 2026, Davidson 2025, Minami 2025, Chauveau 2025, Jiang 2025, Goonewardena 2026, Song 2026, Rubino 2026, Saaskilahti 2026) do not appear in the in-text Findings discussion with attributed specific findings, weakening the source-attribution audit.
• Tuesta-Nole 2026 is described as finding 'no evidence of benefit ... P = 0.58,' but the bundle excerpt does not mention a single P = 0.58; the precise statistic appears unverifiable from the provided source material.
• The 'Holley 2026' levothyroxine emulated target trial in the longevity section is described as reducing CV events (IPTW aHR 0.82, P < 0.0001), which directly contradicts the same paragraph's framing of Tuesta-Nole 2026 (also levothyroxine in SCH) as a directional null — this within-source-class directional conflict is named in the body but not resolved and the magnitudes from the two sources are not synthesized.
• The Ward 2026 / Filev 2026 / Ward 2026 immune-inflammation subsection uses 'Ward 2026' for both the icosapent ethyl MDM study and a separate inflammation finding, creating apparent duplicate citation under one label.
• Several exact statistics (Liu 2026 SBP MD -6.14; Delaney 2025 P = 0.044, P = 0.043; Han 2025 aHR 1.70; Skaarup 2026; Ward 2026 details) cannot be cross-checked from the bundle titles alone and are accepted under the reference-only calibration rule, but the cumulative number of unverifiable precise figures is high enough to warrant caution.
• Gaps section reports '376 claim-level cross-study disagreements' but only names 3 specific tension pairs, which is a large gap between the quantitative claim and the qualitative enumeration.

Reviewer note

This evidence map covers a broad, heterogeneous corpus (64 sources across cardiometabolic, frailty, longevity, muscle, safety, and adjacent outcome classes in older adults) and explicitly declines to converge on a single causal or clinical claim — which is appropriate for the evidence-map genre. Scope and search summary are present, source bundles are traceable, and the Tensions and Gaps section does attempt to surface conflict rather than smooth it away. The headline heterogeneity framing (e.g., the Delaney 2025 positive strawberry finding vs. You/Liu/Young 2026 negative anthropometric-CVD findings at severity 5; sarcopenic-obesity and CKM lenses partly populated) is the kind of faithful disagreement mapping this genre rewards. However, several substantive attribution problems prevent acceptance at this stage: (1) Zheng 2025 is miscoded as null when the bundle reports adverse detraining effects on cardiometabolic risk factors; (2) Young 2026's directional coding as a negative anthropometric-CVD source is not supported by the OLIVAUS DII bundle excerpt; (3) two distinct Chen 2026 papers share one cited_as label, creating audit ambiguity; (4) the within-class directional conflict between Tuesta-Nole 2026 (levothyroxine null) and Holley 2026 (levothyroxine positive for CV events) is named but not resolved; (5) the admissions-funnel arithmetic is internally inconsistent despite the manuscript's own admission that the rows are non-additive; (6) the '58/64 indirect' headline does not reconcile cleanly with the per-slice directness counts; and (7) several findings-map sources do not receive any in-text attribution. These are bounded but material fixes — the map's overall structure and honest heterogeneity framing are sound, but the source-coding errors undermine the per-source audit trail the manuscript stakes its credibility on. Calibration triage: closer to revise than reject because the genre-appropriate breadth is preserved and most findings trace to real sources, but the direction-codec errors and funnel inconsistency are more than wording polish. Source_grounding scores 4 because the underlying bundles largely exist and support most claims, with deductions for the miscoded directional flags. Claim-evidence alignment scores 3 because the coded conflicts overstate some source directions. Synthesis is adequate (3): the map integrates across outcome classes but several tension pairs are incompletely resolved. Research question is present but broad (3): 'cardiovascular subgroups' is a sprawling lens and the five-subgroup scoping is only partly populated. Limitations are present but partly generic (3). Gaps are specific in places but undermined by the 376 disagreement count that is not enumerated (3).

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis